Explore Agilent Technologies' role in advancing infectious disease research through cutting-edge solutions, from in vitro transcribed RNA vaccine testing to biofilm evaluation.
Infection Intel: Staying Ahead with Company Updates and Product Innovations
Countless companies work on improving our lives through research in infectious diseases and prevention. To discover what one company, Agilent Technologies, contributes to the infectious disease and sterile processing fields, Infection Control Today® (ICT®) interviewed Aimee Chiavario, global biopharma segment manager for Agilent Technologies.
Infection preventionists and other personnel involved in infection prevention are hands-on workers who need to know about ongoing and wide-ranging research being conducted behind the scenes to perform their roles safely and effectively.
ICT: Can you elaborate on Agilent's role in supporting scientists globally and its impact on cutting-edge life science research, patient diagnostics, and the testing of water, food, and pharmaceuticals?
Aimee Chiavario: Agilent is a leader in life sciences, diagnostics, and applied chemical markets. We provide laboratories worldwide with instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Our mission is to advance quality of life by focusing our expertise in 6 key markets, including life science research, diagnostics, pharmaceuticals, food, environmental, and chemicals/advanced materials. With a team of approximately 18,000 employees worldwide, our global footprint enables us to deliver high-quality solutions to our valued customers in 110 countries.
Aimee Chiavario
ICT: Given Agilent's diverse areas of focus, particularly in infectious diseases, how does the company contribute to advancements in this field, and what innovative solutions does it offer to address current challenges?
AC: Agilent offers unique and comprehensive analytical solutions to help our customers advance infectious disease research and therapeutic development:
Infection Control Today's Topic of the Month for April: Celebrating Sterile Processing
ICT: In the context of sterile processing, can you share Agilent's approach to ensuring the reliability and accuracy of results in the testing of water, food, and pharmaceuticals, considering the global scale and diverse environments involved?
AC: Agilent ensures the reliability and accuracy of results in testing water, food, and pharmaceuticals by providing high-quality instruments and trusted solutions. Maintaining sterility is important to ensure that the products are free from viable microorganisms that can cause harm to human health. Various methods and technologies can be used to ensure sterility, including:
ICT: Following our previous conversation, have there been any notable developments or advancements in Agilent's technologies, instruments, or services related to sterile processing, and how do these contribute to optimal scientific, economic, and operational outcomes?
AC: Agilent’s latest portfolio of high throughput cell analysis tools enables the assessment of microbial growth, infection, and endotoxins in samples. These methods allow researchers to understand the underlying mechanisms that cause infectious disease and microbial contamination of food, environmental water, and industrial facilities. Additionally, Agilent CrossLab integrates services and consumables to support workflow success, improve productivity, and enhance operational efficiency. This wide range of products and services—from method optimization and training to full-lab relocations and operations analytics—helps laboratories manage their instruments for best performance.
Agilent CrossLab also helps labs reach their sustainability goals by disposing of used parts and packaging in an earth-friendly way with Agilent Green Recycling and extending instrument life to keep equipment out of landfills with proper routine maintenance.
ICT: Considering Agilent's presence in 110 countries, how does the company navigate and adapt to the regulatory landscapes and diverse requirements in different regions regarding sterile processing and ensuring the safety and quality of products in life science research and diagnostics?
AC: Today, regulatory bodies around the globe conduct more frequent audits, including the FDA, the European Medicines Agency, and Japan’s Pharmaceutical Development and Management Association. Agilent recognizes how this impacts customers. Agilent has developed systems, software, and services that integrate seamlessly and work together to handle these challenges confidently. Agilent’s CrossLab compliance consulting services are focused on critical areas such as computer system validation (CSV) for GAMP5 (risk-based approach and V model) and part/annex 11 (electronic records and signatures), audits/assessments for data integrity, and custom procedure writing. An example of custom procedure writing is helping laboratories comply with the 2017 USP <1058> for AIQ.
www.agilent.com/en/solutions/biopharma-pharma/compliance-support-services
www.agilent.com/en/service/laboratory-services/compliance-services/compliance-consulting
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.